—

Versant Venture Management, LLC

Q4 2025 13F Holdings

  • Location
    san francisco, CA
  • Num holdings

    7

  • Value ($000)

    $151,061

  • Date Filed
    02/12/2026
  • Form type
    13F-HR
  • CIK
    0001560009
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
G
GLUE

Monte Rosa Therapeutics, Inc.

COMMON STOCK
61225M102
$68.72M
46 %

4,382,687

L
LENZ

Lenz Therapeutics, Inc.

COMMON STOCK
52635N103
$42.51M
28 %

2,656,888

---

Jade Biosciences, Inc.

COMMON STOCK
008064206
$23.54M
16 %

1,525,820

---

CRISPR Therapeutics AG

COMMON SHARES
H17182108
$7.8M
5 %

148,831

C
CTNM

Contineum Therapeutics, Inc.

COMMON STOCK
21217B100
$6.2M
4 %

542,628

S
SKYE

Skye Bioscience, Inc.

COMMON STOCK
83086J200
$1.51M
1 %

2,007,704

T
TPST

Tempest Therapeutics, Inc.

COMMON STOCK
87978U108
$774.25K
1 %

269,772

Rows Per Page
10
  • 5
  • 10
  • 20
  • 30
  • 50
  • 100
1 - 7 of 7